Innovation in Drug Discovery:
a new role for Basic Research and Academia
IFOM-IEO Campus, Milan, Italy
30th March 2010
New and more powerful drugs are urgently needed for our patients.
Traditionally, basic research on diseases and disease-mechanisms has been conducted in academic institutions, while its application to drug discovery has been the responsibility of the pharmaceutical industry.
In recent years, a strong need has emerged for molecularly-targeted drugs that are based on knowledge of disease-mechanisms. This need has exposed the limitations of conducting basic and applied research separately and has created the basis for new interactions between academia and the pharmaceutical industry.
To address this problem, the European Institute of Oncology has launched today a new Drug Discovery Program, which is fully intertwined with ongoing basic research at the IFOM-IEO Campus. One important aim of the program is to establish collaborations with private and public institutions whose mission is to cure disease.
Invited Speakers
Giulio F. Draetta
Dana Farber Cancer Institute & Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute - Boston, USA
Stephen Hanessian
Dept. of Chemistry, University of Montreal - Montreal, Canada
Steve Jackson
The Gurdon Institute, University of Cambridge - Cambridge, UK
John McCall
Pharmac LLC - Fort Myers, USA
- Leaflet (.pdf, 125 Kb )
ifom-ieo-campus.it - Copyright© IEO